Program Highlights: Scientific Sessions 2017
Eric Peterson, MD, program chair for Scientific Sessions 2017, and Don Lloyd-Jones, MD, ScM, program vice chair, review the highlights of the clinical science planned for the meeting in Anaheim.
- How Do Resuscitation Teams at Top-Performing Hospitals for In-Hospital Cardiac Arrest Differ? A Qualitative Study
RESULTS: In-hospital cardiac arrest resuscitation teams: Clues to what works for a top-performing hospital
- Prehospital Advanced Life Support and Survival After Traumatic Out-of-Hospital Cardiac Arrest: A Cohort Study From the Japanese National Registry
RESULTS: Better 1-month survival when advanced life support (ALS) is provided by physicians for traumatic OHCA patients
- Circulation: Persistent Long-term Structural, Functional and Metabolic Changes after Stress Induced (Takotsubo) Cardiomyopathy
Caroline Scally | University of Aberdeen, Aberdeen, United Kingdom
- JAMA: Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome
Andrew Chapman | University of Edinburgh, Edinburgh, Scotland
- AHA News: Sixth-grader’s science project grows into adult-sized study showing kids can do CPR, too
- AHA News: Many U.S. Latinos aren’t familiar with lifesaving device
- AHA News: Who gets CPR from bystanders? Depends if it’s a man or woman
C. David Mazer, MD summarizes the results of TRICS III, which he presented for Scientific Sessions 2017 in Anaheim.
Sidney C. Smith, Jr, MD, past-president of the American Heart Association, discusses the results of the DACAB trial.
Opening Session: Presidential Address
Late Breaking Clinical Trials 1: CABG and EP Peri-procedural Dilemmas
- TRiCS III
RESULTS: Clinical outcomes for restrictive red cell transfusion strategy not inferior to liberal strategy for cardiac surgery.
RESULTS: Ticagrelor + ASA compared to ASA alone = better CABG saphenous vein graft (SVG) patency at 1 year.
RESULTS: For AF patients on NOAC anticoagulants having device surgery, there was no real difference for continuing vs stopping NOAC’s for surgery; trial stopped early because of low event rates for both arms.
- BRUISE CONTROL-2
RESULTS: For adverse events or contrast-associated acute kidney injury with angiography, no benefit was found with IV sodium bicarbonate vs IV sodium chloride, or oral N-acetylcysteine vs placebo.
- ABRIDGE J
RESULTS: At 3 months after AF catheter ablation, the probability of major bleeding events were less with minimally-interrupted dabigatran when compared to uninterrupted warfarin.
Other studies of note published Sunday
- Circulation: Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation(link opens in new window)
Lu-Chen Weng | Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA
- Circulation: Heart Failure: Contemporary Epidemiology of Heart Failure in Fee-For-Service Medicare Beneficiaries Across Healthcare Settings
Shawn Simek | UT Southwestern Medical Ctr, Dallas, Texas
- JACC: Cardiovascular Interventions: Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Non-Ranked Hospitals in the United States of America
Devraj Sukul |University of Michigan Health System, Ann Arbor, MI
- JACC: Cardiovascular Interventions: Seeking Quality Cardiac Care: Is Public Reporting the Answer?
Gregory J. Dehmer | Temple, TX
- JACC: Sexual Activity as a Trigger for Sudden Cardiac Arrest
Harpriyu Chugh | Cedars-Sinai Medical Center, Los Angeles, CA
- JACC: Five-Year Outcomes in patients with Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction
Gregg Fonarow | University of California, Los Angeles, Los Angeles, CA
- JACC: Long-term Outcomes of Acute Heart Failure – Where are we now?
Benjamin Steinberg | University of Utah, Salt Lake City, UT
- JACC: Effects of Sodium Reduction and the DASH Diet by Level of Baseline Blood Pressure
Stephen Juraschek | Harvard Medical School, Cambridge, MA
- NEJM: Preserve Sodium Bicarbonate and N-Acetylcysteine for the Prevention of Serious Adverse Outcomes Following Angiography
Steven Weisbord | University of Pittsburgh, Pittsburgh, PA
- NEJM: Restrictive or Liberal Red Cell Transfusion for Cardiac Surgery (TRICS-III)
C. David Mazer | Toronto, ON, Canada
- JAMA Cardiology: Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure
Ankur Gupta | Boston, MA
- JAMA Cardiology: Cluster Analysis of Atrial Fibrillation Clinical Phenotypes
Taku Inohara | Duke University Medical Center, Durham, NC
- JAMA Cardiology: Association of LPA Variants With Aortic Stenosis
Hao Yu Chen | McGill University, Montreal, Quebec, Canada
Understanding the 2017 Hypertension Guidelines
John Warner, MD, president of the American Heart Association, interviews Paul Whelton, MD, writing group chair for the 2017 Hypertension Clinical Practice Guidelines and the need for the guidelines, the new classification system, and what it means for clinicians and their patients. Read the guidelines, resources, and complete coverage.
Strategies for Adherence to Treatments for Hypertension
Dan W. Jones, MD, past-president of the American Heart Association, and Paul Whelton, MD, chair of the writing group for the 2017 Hypertension Clinical Practice Guidelines discuss strategies for adherence to treatments for hypertension. Read the guidelines, resources, and complete coverage.
Late Breaking Clinical Trials 2: Late Breaking Science in Prevention
RESULTS: Higher intensity pitavastatin therapy lowered LDL-C and reduced adverse cardiovascular events more than moderate-intensity pitavastatin therapy in this Japanese study population.
RESULTS: Major coronary events lower with anacetrapib for patients with and without DM.
RESULTS: In patients with PAD, evolocumab significantly reduced LDL-C and major cardiovascular events, including death, heart attack, and stroke.
- FOURIER with MI - Analysis
RESULTS: In patients with a prior MI, evolocumab significantly reduced the risk for major cardiovascular events, including death, heart attack, and stroke.
RESULTS: Targeting inflammatory pathways with canakinumab reduced rates of adverse cardiovascular events.
Late Breaking Clinical Trials 3: Latest Insights into Hypertension Management
- BP TITRE
RESULTS: More time spent at the target blood pressure resulted in a lower risk for cardiovascular disease and death.
RESULTS: Blood pressure control was similar even with different levels of BP attendance.
RESULTS: Bariatric surgery reduced the need for antihypertensive drugs while keeping blood pressure controlled.
Late Breaking Clinical Trials 4: Sweet Spot in Cardiometabolic Care
RESULTS: Canagliflozin reduced adverse cardiovascular events for patient with type 2 diabetes and no history of cardiovascular disease.
RESULTS: The treatment effect of exenatide was similar across all risk groups (low – high) for clinical outcomes, regardless of baseline risk. Baseline risk did not predict clinical benefit.
- EMPA-REG OUTCOME
RESULTS: In these patients with HF, T2DM, and PAD, empagliflozin compared to placebo reduced the risk of cardiovascular and all-cause death, and HF hospitalizations.
RESULTS: In the general population, 4 metabolites were noted to be inversely associated with coronary heart disease. This may aid risk stratification.
Other studies of note published Monday
- Circulation: Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study
Jacob A. Udell | University of Toronto, Toronto, ON, Canada
- Circulation: Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomize Trial
Carlos Schiavon | Research Institute, Heart Hospital, São Paulo, Brazil
- Circulation: Potential U.S. Population Impact of the 2017 ACC/AH High Blood Pressure Guideline
Paul Muntner | Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
- Circulation:Availability and Use of Shared Data from Cardiometabolic Clinical Trials
Muthiah Vaduganathan | Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA
- Circulation: Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program
Kenneth Mahaffey | Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, CA
- Circulation: Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME
Subodh Verma | St. Michael's Hospital, Division of Cardiac Surgery, University of Toronto, Ontario, Canada
- Circulation: Burden of Catastrophic Health Expenditures for Acute Myocardial Infarction and Stroke among Uninsured in the United States
Rohan Khera | Division of Cardiology, UT Southwestern Medical Center, Dallas, TX
- Hypertension: Hypertension Clinical Practice Guidelines
Paul Whelton | Tulane University, New Orleans, LA
- JAHA: Deep RNA-sequencing uncovers repertoire of human macrophage lincRNAs that is modulated by macrophage activation and associates with cardiometabolic diseases
Hanrui Zhang | Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY
Christopher Granger, MD, James Jollis, MD, and Mayme Lou Roettig, RN, MSN share the results of STEMI ACCELERATOR-2.
More on the New Hypertension Guidelines
New Guidelines for Proper Blood Pressure Measurement
Dan W. Jones, MD, past-president of the American Heart Association, and Robert M. Carey, MD, writing group co-chair, discuss the 2017 Hypertension Clinical Practice Guidelines for proper blood pressure measurement.
Late Breaking Clinical Trials 5: New Insights into the Risks, Benefits, and Costs of Antithrombotic Therapy
RESULTS: Rivaroxaban + ASA reduced major CV events and direct hospital costs.
- RE-DUAL PCI
RESULTS: Subgroup benefits of dual therapy with dabigatran vs. warfarin triple therapy aligned with the main trial results.
- POISE-2 PCI
RESULTS: For non-cardiac surgery patients and a past history of PCI, the use of perioperative aspirin reduced the risk for death or MI at 30 days after surgery.
RESULTS: The use of P2Y12 inhibitors changed infrequently, possibly because routine pharmacogenomic testing and reporting of CYP2C19 status in ACS patients was low.
RESULTS: Prasugrel versus Ticagrelor showed similar rates of effectiveness (adverse CV events) 1 year after an MI (safety and efficacy).
Late Breaking Clinical Trials 6: Evaluating Quality Improvement and Patient Centered Care Interventions
RESULTS: Over the past 20 years, as evidence-based treatments for NSTEM patients were implemented, long-term survival has improved and the risk for new CV events and HF has improved. (Swedish study)
RESULTS: Tele-pharmacy Intervention improved adherence to medication, but did not improve clinical outcomes.
- ACS QUIK
RESULTS: In this Indian population, the quality improvement toolkit improved process measures (in-hospital and discharge medications), but did not improve the 30-day MACE rates compared to usual care.
RESULTS: An ED tool used to assess ACS in 7 New Zealand hospitals increased the number of patients safely discharged within 6 hours.
RESULTS: A DT LVAD decision support tool improved the quality of decisions with more alignment between the value of the treatment and the patient’s wishes.
- STEMI ACCELERATOR-2
RESULTS: Improvements in regional systems of care was associated with significant reduction in time to STEMI reperfusion, as well as in-hospital mortality.
Other studies of note published Tuesday
- Circulation: Improving Care processes for patients with suspected Acute Coronary Syndrome (ICare-ACS)
Martin Than | Emergency Department, Waikato Hospital, Hamilton, New Zealand
- Circulation: Impact of regionalization of ST elevation myocardial infarction care on treatment times and outcomes for emergency medical services transported patients presenting to hospitals with percutaneous coronary intervention: Mission: Lifeline ACCELERATOR-2
James G. Jollis | Duke Clinical Research Institute, Duke University, Durham, NC and University of North Carolina, Chapel Hill, NC
- Circulation: Cardiovascular Imaging Relationship of Echocardiographic Z-Scores Adjusted for Body Surface Area to Age, Sex, Race, and Ethnicity: The Pediatric Heart Network Normal Echocardiogram Database
Leo Lopez | Herbert Wertheim College of Medicine at Florida International University, Miami, FL
- JACC: Cardiovascular Risk and Statin Eligibility of Young Adults Who Experience a Myocardial Infarction: From the partners YOUNG-MI Registry
Ron Blankstein | Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- JACC: One-year outcomes of patients with acute myocardial infarction treated with primary angioplasty and randomized to prasugrel or ticagrelor
Zuzana Motovska | Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
- JAHA: Disparities in the Quality of Cardiovascular Care Between HIV-Infected versus HIV-Uninfected Adults in the United States: A Cross-Sectional Study
Joseph Ladapo | Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA
- JAMA Internal Medicine: Noninvasive Cardiac Testing vs Clinical Evaluation Alone in Acute Chest Pain
Samuel W. Reinhardt | Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri
Scientific Sessions 2017: What We Learned
Eric Peterson, MD, program chair, and Donald Lloyd-Jones, MD, ScM, program vice chair review the highlights of Scientific Sessions 2017.
Early Career Perspective: Best of Scientific Sessions 2017
Eldrin Lewis, MD, MPH interviews Early Career Bloggers Annie Roessler, Baily De Barmore, and Shayan Mohammadmoradi about their experiences at Scientific Sessions 2017. Read their posts and other bloggers in the Early Career Voice.
New Treatment Approaches for Hypertension
Dan W. Jones, MD, past-president of the American Heart Association, and Paul Whelton, MD, writing group chair, discuss the implications of the 2017 Hypertension Clinical Practice Guidelines for treating patients at various levels of risk.
Managing Hypertension in Patients with Comorbidities
Dan W. Jones, MD, past-president of the American Heart Association, and Robert Carey, MD, writing group co-chair, discuss the implications of the 2017 Hypertension Clinical Practice Guidelines for patients with the comorbidities of diabetes and chronic kidney disease.
Late Breaking Clinical Trials 7: Innovative Therapies and Novel Applications
- REDUCE LAP-HF
RESULTS: 1-month results in HFpEF patients: use of a transcatheter interatrial shunt device (IASD) compared to placebo reduced exercise PCWP.
RESULTS: Epicardial botulinum toxin vs placebo resulted in no significant difference in risk for POAF.
RESULTS: At 12 weeks in PAD patients, 6-minute walking performance was not better with GM-CSF alone or added to supervised treadmill exercise.
RESULTS: At 6 months, the percent change in infarct size after an MI was similar for allogeneic heart stem cells compared to placebo.
RESULTS: MRI results 6 months with intramyocardial cardiosphere-derived cells (CDCs): decrease in myocardial scar and increased inferior systolic wall thickening.
- Circulation: A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2 Randomized, Sham-Controlled Trial
Ted Feldman | NorthShore University Health System, Evanston Hospital, Evanston, IL
- JAMA: Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease
Mary M. McDermott | Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Science News - 2017 Navigation
- 2017 Scientific Sessions and ReSS Abstracts - in Circulation
- ePosters (link opens in new window)(link opens in new window)
- Final Program & Agendas
- Scientific Sessions 2017 Final Program – Digital Flipbook version (opens in new window)(link opens in new window)
- Scientific Sessions 2017 Final Program (PDF version)
- Resuscitation Science Symposium 2017 Final Program (PDF)
- CV Nursing Clinical Symposium Program (PDF)
- Frontiers in Science program agendas
News on Heart.org
Daily news from Anaheim with a consumer focus